OPUS GENETICS INC. -

Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update

12 Nov 2024 07:00:02 By Nasdaq GlobeNewswire

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12 Nov 2024 06:59:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Acquisition of Opus Genetics

22 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

30 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

05 Sep 2024 19:43:59 By Nasdaq GlobeNewswire

Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update

13 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at Two Investor Conferences in August

08 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July

10 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June

06 Jun 2024 06:57:22 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

10 May 2024 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at the Aegis Virtual Conference

03 May 2024 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

11 Apr 2024 09:03:48 By Nasdaq GlobeNewswire

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

01 Apr 2024 06:14:52 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

08 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present in the BIO CEO & Investor Conference

23 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 Feb 2024 15:10:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

14 Feb 2024 07:00:00 By Nasdaq GlobeNewswire